Effectiveness of mask in COVID-19 pandemic in Japan
DOI:
https://doi.org/10.51094/jxiv.381Keywords:
SARS-CoV-2, effective reproduction number, mask, vaccine coverage, waning in vaccine effectivenessAbstract
Background: The government of Japan had stopped to recommend to wear mask on March 13, 2023.
Object: The object of this study was to estimate effectiveness of mask to prevent for COVID-19 infection through comparison among before and after the stopping date.
Method: The effective reproduction number(R(t)) was regressed on dummy variable for after the stopped date as well as vaccine coverage, vaccine coverage with some delay, temperature, humidity, mobility, share of the mutated strains, counter measures including Go To Travel Campaign and an Olympic Games. The study period was February, 2020 through April 14, 2023, as of May 7, 2023.
Results: We selected the specification with 90 days lag of waning. In this specification, the second to the fourth vaccination coverage, the first to the third emergency of status, Goto Travel Campaign and Olympic games and the share of other minor mutated strains were significantly negative. Conversely, share of the alpha, delta, and BA2, BA5, and XBB.1.5 sublineage of omicron variant strain,
The estimated coefficient of after the stopped date for recommendation to wear mask was negative but insignificant.
Discussion: The obtained estimated results showed that mask may not have effectiveness to reduce infection of COVID-19. However, it might suggest that the most of Japanese have continued to wear mask without the government did not recommend after the stopped date.
Conflicts of Interest Disclosure
No author has any conflict of interest, financial or otherwise, to declare in relation to this study.Downloads *Displays the aggregated results up to the previous day.
References
European Centre for Disease Prevention and Control. Epidemiological update: SARS-CoV-2 Omicron sub-lineages BA.4 and BA.5. https://www.ecdc.europa.eu/en/news-events/epidemiological-update-sars-cov-2-omicron-sub-lineages-ba4-and-ba.5. [accessed on January 22, 2023]
National Institute of Infectious Diseases. Updated Situation of COVID-19 Outbreak (July 13,2022) https://www.niid.go.jp/niid/ja/2019-ncov/11309-covid19-ab90th.html (in Japanese) [accessed on January 20, 2023]
Ministry of Health, Labour and Welfare. Visualizing the data: information on COVID-19 infections. https://covid19.mhlw.go.jp/en/ [accessed on February 17, 2023]Kurita J, Sugawara T, Ohkusa Y. Estimating Event Ban Effects on COVID-19 Outbreak in Japan. Journal of Health Science and Development 2021. 4: https://www.innovationinfo.org/articles/JHSD/JHSD-137.pdf
Tokyo metropolitan Government. Data of COVID-19 monitoring meeting in metropolitan Tokyo. https://www.bousai.metro.tokyo.lg.jp/taisaku/saigai/1013388/index.html (in Japanese) [accessed February 21,2023].
Prime Minister of Japan and His Cabinet. COVID-19 Vaccines. https://japan.kantei.go.jp/ongoingtopics/vaccine.html [accessed on February 17, 2023]
Levin EG, Lustig Y, Cohen C, et al. Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. N Engl J Med 2021:NEJMoa2114583.
Chemaitelly H, Tang P, Hasan MR, et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. N Engl J Med. 2021:NEJMoa2114114.
Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383:2603-15.
Chung H, He S, Nasreen S, et al. Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study. BMJ 2021;374.
Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, Hernan MA, Lipsitch M, Reis B, Balicer RD. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med 2021;384:1412-23.
Vasileiou E, Simpson CR, Shi T, et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet 2021;397:1646-57.
Bernal JL, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, Simmons R, Cottrell S, Roberts R, O'Doherty M, Brown K, Cameron C, Stockton D, McMenamin J, Ramsay M. Effectiveness of the Pfizer–BioNTech and Oxford–AstraZeneca vaccines on Covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ 2021;373:n1088.
Bjork J, Inghammar M, Moghaddassi M, Rasmussen M, Malmqvist U, Kahn F. Effectiveness of the BNT162b2 vaccine in preventing COVID-19 in the working age population: first results from a cohort study in southern Sweden. Infect Dis (Lond) 2021;1-6.
Pawlowski C, Lenehan P, Puranik A, Agarwal V, Venkatakrishnan AJ, Niesen MJM, O'Horo JC, Virk A, Swift MD, Badley AD, Halamka J, Soundararajan V. FDA-authorized COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system. Med (N Y) 2021;2:979-92.e8.
Li B, Deng A, Li K, et al. Viral infection and transmission in a large, well-traced outbreak caused by the SARS-CoV-2 Delta variant. medRxiv 2021.07.07.21260122; doi: https://doi.org/10.1101/2021.07.07.21260122
Downloads
Posted
Submitted: 2023-05-18 05:29:41 UTC
Published: 2023-05-19 10:41:39 UTC
Versions
- 2023-06-22 09:58:32 UTC (2)
- 2023-05-19 10:41:39 UTC (1)
Reason(s) for revision
License
Copyright (c) 2023
Junko Kurita
Tamie Sugawara
Yasushi Ohkusa
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
